Table 1.
Descriptive Baseline Sample Statistics of the Florida Cohort Study stratified by Antiretroviral Therapy Adherence and Viral Suppression
| Adherenta |
Nonadherenta |
Suppressedb |
Nonsuppressedb |
|
|---|---|---|---|---|
| n (%) |
n (%) |
n (%) |
n (%) |
|
| n = 535 | n = 238 | n = 659 | n = 220 | |
| Age group | ||||
| 18–34 | 76 (14.2) | 41 (17.2) | 89 (13.5) | 60 (27.3) |
| 35–44 | 90 (16.8) | 54 (22.7) | 122 (18.5) | 51 (23.2) |
| 45–54 | 222 (41.5) | 90 (37.8) | 261 (39.6) | 83 (37.7) |
| ≥55 | 147 (27.5) | 53 (22.3) | 187 (28.4) | 26 (11.8) |
| Race | ||||
| White | 200 (37.5) | 60 (25.2) | 223 (33.9) | 58 (26.5) |
| Black | 282 (52.9) | 152 (63.9) | 370 (56.2) | 140 (63.9) |
| Other | 51 (9.6) | 26 (10.9) | 65 (9.9) | 21 (9.6) |
| Ethnicity | ||||
| Non-Hispanic | 426 (79.6) | 191 (80.3) | 518 (78.6) | 184 (83.6) |
| Hispanic | 109 (20.4) | 47 (19.7) | 141 (21.4) | 36 (16.4) |
| Sex | ||||
| Male | 356 (66.5) | 153 (64.3) | 420 (63.7) | 154 (70.0) |
| Female | 179 (33.5) | 85 (35.7) | 239 (36.3) | 66 (30.0) |
| Sexual orientation | ||||
| Heterosexual | 258 (50.6) | 132 (56.7) | 347 (54.5) | 109 (52.7) |
| Nonheterosexual | 252 (49.4) | 101 (43.3) | 290 (45.5) | 98 (47.3) |
| General enacted HIV-related stigma | ||||
| None | 249 (48.3) | 98 (42.2) | 299 (47.3) | 100 (47.0) |
| Low/moderate | 206 (39.9) | 93 (40.1) | 250 (39.6) | 80 (37.5) |
| High | 61 (11.8) | 41 (17.7) | 83 (13.1) | 33 (15.5) |
| Health care specific enacted stigma | ||||
| Not experienced | 481 (91.3) | 199 (85.0) | 579 (90.2) | 195 (89.5) |
| Experienced | 46 (8.7) | 35 (15.0) | 63 (9.8) | 23 (10.5) |
| Mental health factor | ||||
| Low risk | 170 (33.9) | 45 (20.4) | 197 (32.6) | 42 (20.4) |
| Medium risk | 119 (23.8) | 56 (25.3) | 137 (22.7) | 48 (23.3) |
| High risk | 212 (42.3) | 120 (54.3) | 270 (44.7) | 116 (56.3) |
| Socioeconomic factor | ||||
| Low risk | 146 (29.3) | 55 (24.3) | 179 (29.0) | 45 (21.9) |
| Medium risk | 109 (21.9) | 42 (18.6) | 127 (20.5) | 44 (21.5) |
| High risk | 243 (48.8) | 129 (57.1) | 312 (50.5) | 116 (57.6) |
| Social support factor | ||||
| Low risk | 131 (26.4) | 55 (24.2) | 160 (26.3) | 44 (22.0) |
| Medium risk | 132 (26.6) | 47 (20.7) | 155 (25.5) | 47 (23.5) |
| High risk | 233 (47.0) | 125 (55.1) | 293 (48.2) | 109 (54.5) |
| Noninjection drug use factor | ||||
| Low risk | 247 (51.5) | 83 (39.5) | 296 (50.4) | 84 (42.4) |
| Medium risk | 83 (17.3) | 42 (20.0) | 110 (18.7) | 32 (15.2) |
| High risk | 150 (31.2) | 85 (40.5) | 181 (30.8) | 84 (42.4) |
| Injection drug use factor | ||||
| Low risk | 388 (78.1) | 163 (72.4) | 459 (75.1) | 167 (80.3) |
| Medium risk | 87 (17.5) | 38 (16.9) | 115 (18.8) | 21 (10.1) |
| High risk | 22 (4.4) | 24 (10.7) | 37 (6.1) | 20 (9.6) |
| Usual place of care factor | ||||
| Low risk | 490 (92.8) | 225 (94.9) | 601(92.8) | 179 (82.1) |
| High risk | 38 (7.2) | 12 (5.1) | 47 (7.2) | 39 17.9) |
a
Antiretroviral therapy adherence was dichotomized based on a ≥95% adherence cutpoint.
b
Viral suppression was dichotomized based on a 200 viral copies/mL cutpoint.